Sight Sciences, Inc. (SGHT) Stock Price & Analysis
Sight Sciences, Inc. (SGHT) rose 4.75% to USD 4.85 as of June 10, 2026 at 02:13 UTC, according to Nexqual real-time market data.
SGHT last closed at USD 4.63; the session ranged USD 4.7–5 on volume of 144,126 shares. Market capitalization is $263.89M, with a 52-week range of USD 3.11–9.24 (NMS). Source: Nexqual, June 10, 2026 at 02:13 UTC.
Key Statistics (as of June 10, 2026 at 02:13 UTC)
| Price | USD 4.85 |
|---|---|
| Change | ▲ 4.75% (up) |
| Previous Close | USD 4.63 |
| Open | USD 4.7 |
| Day Range | USD 4.7 – 5 |
| 52-Week Range | USD 3.11 – 9.24 |
| Volume | 144,126 shares |
| Market Cap | $263.89M |
| Exchange | NMS |
Technical Analysis (SGHT)
Nexqual's technical model rates SGHT "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 02:13 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.5 (neutral) |
| vs SMA50 | Above (USD 4.38) |
| MACD | 0.02 (positive) |
Analyst Ratings (SGHT)
Wall Street analysts rate SGHT "Buy" based on 4 analysts, with a mean price target of USD 8.54 (range USD 5.15–12), per Nexqual as of June 10, 2026 at 02:13 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 8.54 |
| High Target | USD 12 |
| Low Target | USD 5.15 |
| Buy / Hold / Sell | 4 / 2 / 0 |
Earnings (SGHT)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.17 |
| Revenue Estimate | $21.69M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.24 vs est -0.2 ▼ miss |
| 2025-12-31 | USD -0.08 vs est -0.14 ▲ beat |
| 2025-09-30 | USD -0.16 vs est -0.26 ▲ beat |
| 2025-06-30 | USD -0.23 vs est -0.28 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:13 UTC.
Financials & Fundamentals (SGHT)
| Total Revenue | $79.55M |
|---|---|
| Revenue Growth (YoY) | +12.50% |
| Gross Margin | +86.17% |
| Operating Margin | -35.60% |
| Profit Margin | -46.83% |
| ROE | -56.64% |
| Debt / Equity | 77.47 |
| Current Ratio | 5.86 |
| Total Cash | $84.96M |
| Total Debt | $41.76M |
| Free Cash Flow | $-8.58M |
Source: Nexqual, June 10, 2026 at 02:13 UTC.
Financial Health Score (SGHT)
Nexqual rates Sight Sciences, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:13 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 86%, operating -36% |
| Balance Sheet | Mixed — $85M cash vs $42M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$9M, burning cash |
| Efficiency | Critical — ROE -57%, ROA -14.3% |
Ownership (SGHT)
| Insider Ownership | +20.27% |
|---|---|
| Institutional Ownership | +53.95% |
| Shares Outstanding | 54.41M |
| Float | 35.37M |
| Short % of Float | +2.26% |
Source: Nexqual, June 10, 2026 at 02:13 UTC.
Leadership (SGHT)
Sight Sciences, Inc. is led by Paul Badawi (age 49), Co-Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 02:13 UTC.
| Co-Founder, President, CEO & Director | Paul Badawi (age 49) |
|---|---|
| Chief Operating Officer | Alison Perry Bauerlein (age 44) |
| Co-Founder, CTO & Director | David Badawi (age 54) |
| CFO & Treasurer | James Rodberg (age 41) |
| Executive Vice President of Operations and R & D | Brenton Taylor (age 44) |
Major Backers & Investors (SGHT)
Notable institutional backers of Sight Sciences, Inc. include Long Focus Capital Management, LLC, Pathstone Holdings, LLC, Americana Partners, LLC, according to Nexqual as of June 10, 2026 at 02:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Long Focus Capital Management, LLC | 6.61% |
| Pathstone Holdings, LLC | 4.41% |
| Americana Partners, LLC | 3.09% |
| B Group, Inc. | 1.78% |
| Acadian Asset Management. LLC | 1.42% |
| Fidelity | 1.1% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.02% |
| Vanguard Group | 5.66% |
| Geode Capital | 1.68% |
| State Street | 1.53% |
Source: Nexqual, June 10, 2026 at 02:13 UTC.
From Sight Sciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States.
- The company operates in two segments, Surgical Glaucoma and Dry Eye.
- It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology.
- It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CTKB | Cytek Biosciences, Inc. | USD 4.13 | ▲ 0.98% |
| RPID | Rapid Micro Biosystems, Inc. | USD 1.88 | ▼ 5.53% |
| TMCI | Treace Medical Concepts, Inc. | USD 3.73 | ▲ 6.27% |
| RXST | RxSight, Inc. | USD 4.91 | ▼ 1.8% |
| DSGN | Design Therapeutics, Inc. | USD 10.55 | ▼ 0.94% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:13 UTC. This page is informational and not investment advice.